Sponsors (3)
The bill strengthens definitions, enforcement coordination, reporting, and prevention efforts to reduce counterfeit fentanyl/meth harms and improve public awareness, but does so at the cost of greater criminal exposure for some individuals, increased costs and legal uncertainty for businesses and agencies, and potential emphasis on enforcement over treatment and transparency.
Young people, patients, and families are better protected because the bill clarifies and expands definitions of counterfeit or product-mimicking fentanyl/methamphetamine, making it easier for authorities to identify, remove dangerous products from circulation, and prosecute clear cases.
Parents, schools, and communities gain stronger prevention and public-awareness efforts because the bill requires auditing and data-driven tailoring of campaigns to youth and other groups, which should raise awareness and reduce accidental ingestion and overdoses over time.
Federal and local law enforcement and Congress gain centralized data and clearer coordination—through required reporting and clarified investigative strategies—improving oversight, strategy-sharing, and targeting of counterfeit fentanyl/meth interdiction.
Low-income sellers, casual distributors, and community members face increased risk of criminal liability because broader or clarified definitions and enforcement emphasis may capture people who unknowingly handle contaminated or counterfeit products.
Small businesses, federal agencies, and taxpayers could see higher costs because of increased compliance, seizure exposure for businesses, expanded DEA operational activity, and additional agency workload to compile/redact required reports.
Communities may experience greater policing and criminalization rather than expanded treatment-focused responses because the bill emphasizes enforcement and seizures, which can exacerbate harms in affected neighborhoods.
Based on analysis of 5 sections of legislative text.
Defines counterfeit fentanyl/methamphetamine, broadens federal prohibited-act language, requires a DEA response plan and annual DOJ/DEA/ONDCP reports on seizures, prosecutions, and prevention.
Creates a federal definition of “counterfeit fentanyl or methamphetamine” and requires the Drug Enforcement Administration to build a focused operational and response plan to address such counterfeit pills and substances. It also amends a Controlled Substances Act provision to expand enforcement scope and directs the Department of Justice, DEA, and ONDCP to report to Congress within one year and annually on seizures, prosecutions, and prevention actions.
Introduced October 30, 2025 by Charles Ernest Grassley · Last progress October 30, 2025